Moderna (MRNA), the biotechnology and vaccine manufacturer, gained 7% after beating third quarter earnings expectations. The company raised its FY26 revenue growth outlook to between 15% and 25%, from a previous ceiling of 10%.
Join our Mailing list!
Sign up to get all the latest financial news and business updates.
Please fill in the form and we will get in touch with you shortly and help answer any questions you may have about Offshore Supporting services.
